scholarly journals Weight control is vital for patients with early-stage endometrial cancer or complex atypical hyperplasia who have received progestin therapy to spare fertility: a systematic review and meta-analysis

2019 ◽  
Vol Volume 11 ◽  
pp. 4005-4021 ◽  
Author(s):  
Miaomiao Li ◽  
Tao Guo ◽  
Ran Cui ◽  
Ying Feng ◽  
Huimin Bai ◽  
...  
Keyword(s):  
Systematic Review ◽  
Endometrial Cancer ◽  
Weight Control ◽  
Early Stage ◽  
Meta Analysis ◽  
Atypical Hyperplasia ◽  
Progestin Therapy ◽  
Early Stage Endometrial Cancer

Oral Progestin Treatment for Early-Stage Endometrial Cancer: A Systematic Review and Meta-analysis

2016 ◽  
Vol 26 (6) ◽  
pp. 1081-1091 ◽  
Author(s):  
Yun Qin ◽  
Zhizhi Yu ◽  
Jiaxin Yang ◽  
Dongyan Cao ◽  
Mei Yu ◽  
...  
Keyword(s):  
Systematic Review ◽  
Endometrial Cancer ◽  
Early Stage ◽  
Body Weight Gain ◽  
Meta Analysis ◽  
Live Birth Rate ◽  
Reproductive Age ◽  
Final Sample ◽  
Progestin Treatment ◽  
Early Stage Endometrial Cancer

ObjectiveThis study aimed to evaluate the efficacy and safety of oral progestin treatment for early-stage endometrial cancer.MethodsWe conducted a systematic review and meta-analysis of the proportions from observational studies. Original studies were selected if patients with early-stage endometrial cancer, especially those of reproductive age, were treated with oral progestin. We conducted searches on studies listed in MEDLINE, EMBASE, and Cochrane that were published through June 2014, and relevant articles were also searched. The methodological quality of the included studies was assessed using the Newcastle-Ottawa quality assessment scale. Funnel plots and metaregression analyses were used to assess bias.ResultsThe final sample included 25 articles involving 445 patients. Based on a random-effects model, patients achieved a disease regression rate of 82.4% (95% confidence interval [CI], 75.3%–88.7%), a relapse rate of 25.0% (95% CI, 15.8%–35.2%), a pregnancy rate of 28.8% (95% CI, 22.5%–35.5%), and a live birth rate of 19.6% (95% CI, 12.8%–27.4%). Body weight gain, liver dysfunction, and abnormal blood coagulation test results were the most common treatment-related adverse effects. Only 2 disease-related deaths were reported during the follow-up duration.ConclusionsBased on the present systematic review and meta-analysis, oral progestin treatment is feasible and safe for patients of reproductive age.

scholarly journals The Oncology Safety of Diagnostic Hysteroscopy in Early-Stage Endometrial Cancer: A Systematic Review and Meta-Analysis

2021 ◽  
Vol 11 ◽  
Author(s):  
Yi Du ◽  
Yu Xu ◽  
Zhaojuan Qin ◽  
Liang Sun ◽  
Yali Chen ◽  
...  
Keyword(s):  
Systematic Review ◽  
Endometrial Cancer ◽  
Early Stage ◽  
Meta Analysis ◽  
Disease Free Survival ◽  
Developed Countries ◽  
Cochrane Library ◽  
Cancer Disease ◽  
Oncological Safety ◽  
Early Stage Endometrial Cancer

BackgroundHysteroscopy is becoming a common method for the diagnosis of uterine disorders in developed countries. However, hysteroscopy might worsen the prognosis of endometrial cancer because it could cause cancer dissemination into the peritoneal cavity through the fallopian tubes. Objective: The aim of this systematic review and meta-analysis was to explore the oncological safety of hysteroscopy for early-stage endometrial cancer.Search StrategyEligible studies were obtained from PubMed, Embase, and the Cochrane Library up to September 22, 2020.Selection CriteriaStudies which compared the oncological safety of hysteroscopy with other methods were included.Data Collection and AnalysisA total of 3980 patients were included in this study, of whom1357 patients had undergone hysteroscopy and2623 had not.Main ResultsThere was no significant association between hysteroscopy and worse prognosis in early-stage endometrial cancer [disease-free survival: log risk ratio(logRR) -0.22; 95% confidence interval (CI), -0.54 to 0.1; p=0.97; overall survival: logRR 0.03; 95% CI, -0.05 to 0.11; p=0.02; disease-specific survival: logRR 0.03; 95% CI, -0.03 to 0.10; p=0.00].ConclusionThis study suggests that hysteroscopy is a safe diagnostic and treatment method, and has no significant effect on the prognosis of early-stage endometrial cancer.Systematic Review RegistrationPROSPERO registration number: CRD42020193696.

Survival Impact of Ovarian Preservation on Women With Early-Stage Endometrial Cancer: A Systematic Review and Meta-analysis

2016 ◽  
Vol 27 (1) ◽  
pp. 77-84 ◽  
Author(s):  
Haifeng Gu ◽  
Jundong Li ◽  
Yangkui Gu ◽  
Hua Tu ◽  
Yun Zhou ◽  
...  
Keyword(s):  
Endometrial Cancer ◽  
Early Stage ◽  
Meta Analysis ◽  
Grey Literature ◽  
Disease Free Survival ◽  
Premenopausal Women ◽  
Cochrane Library ◽  
Ovarian Preservation ◽  
Significant Difference ◽  
Early Stage Endometrial Cancer

ObjectiveThe aim of this article was to investigate the survival impact of ovarian preservation in surgically treated patients with early-stage endometrial cancer using a meta-analysis.MethodsMajor online databases, including PubMed, EMBASE, Web of Science, the Cochrane Library, as well as Grey Literature database, were searched to collect studies on the effects of ovarian preservation compared with bilateral salpingo-oophorectomy (BSO) for surgical treatment in endometrial cancer patients. The literature search was performed up to April 2016. The results were analyzed using RevMan 5.0 software and Stata/SE 12.0 software.ResultsTotally, 7 retrospective cohort studies including 1419 patients in ovarian preservation group and 15,826 patients in BSO group were enrolled. Meta-analysis showed that there was no significant difference in overall survival between the patients treated with ovarian preservation and BSO (hazards ratio [HR], 1.00; 95% confidence interval [CI], 0.72–1.39; P = 1.00). Similar result was achieved in the young and premenopausal women (HR, 0.99; 95% CI, 0.70–1.39; P = 0.39). Furthermore, the disease-free survival of patients whose ovaries were preserved was slightly compromised but with no statistical significance (HR, 1.49; 95% CI, 0.56–3.93; P = 0.42).ConclusionsOvarian preservation may be safe in patients with early-stage endometrial cancer, and it could be cautiously considered in treating young and premenopausal women because it is not associated with an adverse impact on the patients’ survival. Given the inherent limitations of the included studies, further well-designed randomized controlled trial are needed to confirm and update this analysis.

scholarly journals Therapeutic role of systematic lymphadenectomy in early-stage endometrial cancer: A systematic review

2016 ◽  
Vol 11 (6) ◽  
pp. 3849-3857 ◽  
Author(s):  
MEI-YI LI ◽  
XIAO-XIA HU ◽  
JIAN-HONG ZHONG ◽  
LU-LU CHEN ◽  
YONG-XIU LIN
Keyword(s):  
Systematic Review ◽  
Endometrial Cancer ◽  
Early Stage ◽  
Therapeutic Role ◽  
Systematic Lymphadenectomy ◽  
Early Stage Endometrial Cancer

scholarly journals Weight Loss Improves Pregnancy and Livebirth Outcomes in Young Women with Early-Stage Endometrial Cancer and Atypical Hyperplasia

2021 ◽  
Vol Volume 13 ◽  
pp. 5711-5722
Author(s):  
Yanfang Zhang ◽  
Dan Li ◽  
Qi Yan ◽  
Xueru Song ◽  
Wenyan Tian ◽  
...  
Keyword(s):  
Weight Loss ◽  
Endometrial Cancer ◽  
Young Women ◽  
Early Stage ◽  
Atypical Hyperplasia ◽  
Early Stage Endometrial Cancer

The role of genetic and epigenetic changes in the development of atypical hyperplasia and early-stage endometrial cancer

2021 ◽  
Vol 5_2021 ◽  
pp. 48-54
Author(s):  
Gadzhieva L.T. Gadzhieva L ◽  
Pronin S.M. Pronin ◽  
Pavlovich S.V. Pavlovich S ◽  
Kiselev V.I. Kiselev V ◽  
◽  
...  
Keyword(s):  
Endometrial Cancer ◽  
Early Stage ◽  
Atypical Hyperplasia ◽  
Epigenetic Changes ◽  
Early Stage Endometrial Cancer
Sign in / Sign up

Export Citation Format

Share Document